Ruxolitinib targets DCs: for better or worse?

The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting

(2013) Miriam Merad et al.   Annual Review of Immunology

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

(2010) A Pardanani et al.   LEUKEMIA

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE